Abstract
ABSTRACTDecorin (DCN) is a small extracellular proteoglycan with significant oncosuppressive activity. Lung adenocarcinoma is commonly devoid of DCN expression and is a leading cause of cancer mortality globally. As a proof‐of‐concept study for evaluating the oncosuppressive potential of DCN expression in lung adenocarcinoma cells, we constructed an oncolytic herpes simplex virus type 1 (HSV‐1) vector, with a DCN transgene, using a transfection‐infection method. Treatment of the lung adenocarcinoma cell line A549 with this novel DCN‐expressing HSV‐1 vector led to a significantly increased oncolysis of the cells compared to the effect of the parental or control marker virus. These results support the further development of a DCN‐expressing oncolytic HSV‐1 for evaluation in in vivo models for the treatment of lung adenocarcinoma, as well as other types of cancers with underexpressed DCN.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call